Kim Tipton is a seasoned professional in the biopharmaceutical industry, currently serving as the Director of Clinical Science at Celcuity since March 2025. Prior to that, Kim held the position of Director of Clinical Science at ALX Oncology, where contributions included leading clinical trials for innate-immune targeted therapies. Kim's extensive experience encompasses senior roles at CRISPR Therapeutics, focusing on allogeneic CAR T cell therapies, and positions at pH Pharma, CytomX Therapeutics, Catalyst Biosciences, and UC Berkeley, with a strong emphasis on immuno-oncology and novel therapeutics. Educational credentials include a PhD in Cellular and Molecular Biology from the University of California, San Francisco, alongside a BS in Microbiology and a BA in English Literature from The University of Texas at Austin.
This person is not in any teams
This person is not in any offices